Johnson & Johnson (J&J) has decided to pause its proposed changes to the 340B drug discount program after facing resistance from the Health Resources and Services Administration (HRSA) and pressure from hospitals and federal officials. This development underscores the tensions between pharmaceutical companies and the government over the implementation and oversight of the 340B program, which offers discounted medications to hospitals and clinics serving low-income populations.
J&J’s proposal, initially slated to start mid-October, would have required entities covered under the 340B program to pay the full price for two specific medications—Stelara, a treatment for plaque psoriasis, and Xarelto, a blood thinner—before filing a rebate claim. J&J argued this approach was needed to address what it sees as program misuse, particularly concerning duplicate discounts where entities receive both 340B discounts and Medicaid rebates, a violation of federal statutes.
The HRSA strongly opposed J&J’s planned rebate model, labeling it “inconsistent” with the statutory requirements and warning J&J that proceeding without prior HRSA approval could result in the termination of the company’s pharmaceutical pricing agreement and potential referral to the Department of Health and Human Services’ Office of the Inspector General. As conveyed in a Sept. 27 letter to J&J from HRSA, the repercussions of such a termination are significant, affecting millions of Medicare and Medicaid patients’ access to essential medications.
Despite stepping back from immediate changes, J&J maintains that its strategy is within the legal framework and necessary for compliance with both the 340B statute and the Inflation Reduction Act directives. The company highlighted ongoing efforts to address program abuses through HRSA-approved audits of covered entities but expressed frustration over the lack of cooperation from these entities, some of whom have pursued legal actions to counteract J&J’s audit processes.
J&J has hinted at further legal actions to uphold its proposed model, emphasizing in their communications that they “reserve all of its legal rights” regarding this issue. Meanwhile, as J&J considers its next steps, the 340B program’s oversight and the balance between aiding underserved hospitals and managing pharmaceutical interests remain contentious.
The 340B program has been a source of alleged exploitation and insufficient supervision by the pharmaceutical industry since its inception in 1992. With recent developments, J&J’s encounter with HRSA reflects broader challenges facing drug manufacturers who seek to navigate complex regulatory landscapes while pursuing corporate goals. For further insights, see the original report on MedCity News.